Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.35 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256209 | 0.78 | CCR1 (0.45) | CAMKK1CAMKK2NOTUMDYRK1AABL1 | |
| SCHEMBL30292976 | 0.78 | CCR1 (0.45) | CAMKK1CAMKK2NOTUMDYRK1AABL1 | |
| SCHEMBL23619423 | 0.78 | NCF1 (0.41) | NCF1NR4A2SOS2NUDT1CYP17A1 | |
| SCHEMBL13482934 | 0.77 | NCF1 (0.37) | NCF1NR4A2SOS2PIK3CBNUDT1 | |
| SCHEMBL12146924 | 0.76 | NCF1 (0.39) | NCF1NR4A2SOS2NUDT1CYP17A1 | |
| SCHEMBL13713238 | 0.76 | CAMKK1 (0.36) | CAMKK1CAMKK2NOTUMHRH4DYRK1A | |
| SCHEMBL10222527 | 0.76 | F2RL1 (0.38) | CAMKK1CAMKK2NOTUMDYRK1AABL1 | |
| SCHEMBL21855983 | 0.76 | CAMKK1 (0.36) | CAMKK1CAMKK2NOTUMHRH4DYRK1A | |
| SCHEMBL20674217 | 0.76 | NOTUM (0.40) | CAMKK1CAMKK2NOTUMHRH4MAP4K1 | |
| SCHEMBL6951047 | 0.76 | MGAM (0.38) | CAMKK1CAMKK2NOTUMHRH4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-119707930-A | Aromatic ring compound and its prepn and use | 甘李药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4272832-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7704925-B2 | Ligational encoding using building block oligonucleotides | NUEVOLUTION A/S (DK) | 2010-04-27 | — | — | US | disclosed |
| EP-1742945-B1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20090011957-A1 | Ligational encoding using building block oligonucleotides | NUEVOLUTION A/S (DK) | 2009-01-08 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1742945-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | NCF1 521/4885CAMKK1 2303/4885CAMKK2 2942/4885 |
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | NCF1 563/4885CAMKK1 2306/4885CAMKK2 2939/4885 |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | NCF1 556/4885CAMKK1 4109/4885CAMKK2 4291/4885 |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | NCF1 447/4885CAMKK1 2097/4885CAMKK2 2652/4885 |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | TYMP, DPYD, HPRT1 | NCF1 1658/4885CAMKK1 2706/4885CAMKK2 2775/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | NCF1 1874/4885CAMKK1 721/4885CAMKK2 523/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | NCF1 883/4885CAMKK1 3941/4885CAMKK2 4133/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | NCF1 414/4885CAMKK1 2072/4885CAMKK2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.